JAZZ Company Profile
✉ Email this page to a colleague
What is the competitive landscape for JAZZ, and what generic alternatives to JAZZ drugs are available?
JAZZ has seven approved drugs.
There are forty-nine US patents protecting JAZZ drugs.
There are two hundred and fifty-six patent family members on JAZZ drugs in thirty-two countries and ninety-three supplementary protection certificates in thirteen countries.
Summary for JAZZ
International Patents: | 256 |
US Patents: | 49 |
Tradenames: | 7 |
Ingredients: | 7 |
NDAs: | 7 |
Patent Litigation for JAZZ: | See patent lawsuits for JAZZ |
PTAB Cases with JAZZ as patent owner: | See PTAB cases with JAZZ as patent owner |
Drugs and US Patents for JAZZ
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jazz Pharms | XYREM | sodium oxybate | SOLUTION;ORAL | 021196-001 | Jul 17, 2002 | RX | Yes | Yes | 9,486,426*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | 11,207,292 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Jazz | XYWAV | calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate | SOLUTION;ORAL | 212690-001 | Jul 21, 2020 | RX | Yes | Yes | 10,213,400*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | 11,446,258 | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for JAZZ
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Jazz | FAZACLO ODT | clozapine | TABLET, ORALLY DISINTEGRATING;ORAL | 021590-002 | Feb 10, 2004 | 6,221,392 | ⤷ Sign Up |
Jazz | FAZACLO ODT | clozapine | TABLET, ORALLY DISINTEGRATING;ORAL | 021590-002 | Feb 10, 2004 | 5,178,878 | ⤷ Sign Up |
Jazz | FAZACLO ODT | clozapine | TABLET, ORALLY DISINTEGRATING;ORAL | 021590-003 | Jun 3, 2005 | 6,221,392 | ⤷ Sign Up |
Jazz | FAZACLO ODT | clozapine | TABLET, ORALLY DISINTEGRATING;ORAL | 021590-004 | May 30, 2007 | 5,178,878 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for JAZZ drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Extended-release Capsules | 100 mg | ➤ Subscribe | 2009-04-20 |
➤ Subscribe | Extended-release | 150 mg | ➤ Subscribe | 2009-04-13 |
➤ Subscribe | Oral Solution | 500 mg/mL | ➤ Subscribe | 2010-07-08 |
International Patents for JAZZ Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Portugal | 3206715 | ⤷ Sign Up |
European Patent Office | 3695833 | ⤷ Sign Up |
Singapore | 11201505029Q | ⤷ Sign Up |
Mexico | 352085 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for JAZZ Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1856135 | LUC00153 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: FOSTAMATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, OU UN HYDRATE, SOLVATE OU N-OXYDE DE FOSTAMATINIB OU LE SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, EN PARTICULIER FOSTAMATINIB DISODIUM, EVENTUELLEMENT SOUS FORME D'HYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/19/1405 20200113 |
0933372 | 13/2008 | Austria | ⤷ Sign Up | PRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713 |
2822954 | LUC00083 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; AUTHORISATION NUMBER AND DATE: EU/1/18/1289 20180625 |
0806968 | SPC/GB07/011 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.